More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.

ABSTRACT:

Objective

To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY.

Design

Global (15 countries), multicentre, non-interventional study (2004-2017).

Methods

The complete ACROSTUDY cohort comprised patients with acromegaly, who were being treated with pegvisomant (PEGV) prior to the study or at enrolment. The main endpoints were long-term safety (comorbidities, adverse events (AEs), pituitary tumour volumes, liver tests) and efficacy (IGF1 changes).

Results

Patients (n = 2221) were treated with PEGV for a median of 9.3 years (range, 0-20.8 years) and followed up for a median of 7.4 years (range, 0-13.9 years). Before PEGV, 96.3% had received other acromegaly treatments (surgery/radiotherap

SUBMITTER: Fleseriu M 

PROVIDER: S-EPMC8428076 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature